Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.

@article{Medhi2010ResponseAO,
  title={Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.},
  author={Kunjahari Medhi and Vinod Raina and Lalit Kumar and Atul Rai Sharma and Sameer Bakhshi and Ritu Gupta and Rajive Kumar},
  journal={Leukemia & lymphoma},
  year={2010},
  volume={51 10},
  pages={1850-4}
}
Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is a standard of care for chronic myeloid leukemia (CML). There are few publications on responses of patients with CML from the Indian subcontinent. This study analyzed the response rate, progression-free survival (PFS), overall survival (OS), and toxicities in patients with CML given imatinib. Analysis included patients with CML who received imatinib under the GIPAP program at our institution from January 2002 to December 2008… CONTINUE READING